Trials / Completed
CompletedNCT05022784
Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
Real-World Medication Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,798 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 66 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: * Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients. * Understanding characteristics of patients within each nintedanib adherence trajectory among IPF patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | Nintedanib |
Timeline
- Start date
- 2021-08-23
- Primary completion
- 2021-12-30
- Completion
- 2021-12-30
- First posted
- 2021-08-26
- Last updated
- 2024-04-19
- Results posted
- 2024-04-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05022784. Inclusion in this directory is not an endorsement.